Bockarie Moses J, Tisch Daniel J, Kastens Will, Alexander Neal D E, Dimber Zachary, Bockarie Florence, Ibam Ervin, Alpers Michael P, Kazura James W
Papua New Guinea Institute of Medical Research, Goroka, Madang, Papua New Guinea.
N Engl J Med. 2002 Dec 5;347(23):1841-8. doi: 10.1056/NEJMoa021309.
The global initiative to eradicate bancroftian filariasis currently relies on mass treatment with four to six annual doses of antifilarial drugs. The goal is to reduce the reservoir of microfilariae in the blood to a level that is insufficient to maintain transmission by the mosquito vector.
In nearly 2500 residents of Papua New Guinea, we prospectively assessed the effects of four annual treatments with a single dose of diethylcarbamazine plus ivermectin or diethylcarbamazine alone on the incidence of microfilariae-positive infections, the severity of lymphatic disease, and the rate of transmission of Wuchereria bancrofti by mosquitoes. Random assignment to treatment regimens was carried out according to the village of residence, and villages were categorized as having moderate or high rates of transmission.
The four annual treatments with either drug regimen were taken by 77 to 86 percent of the members of the population who were at least five years old; treatments were well tolerated. The proportion with microfilariae-positive infections decreased by 86 to 98 percent, with a greater reduction in areas with a moderate rate of transmission than in those with a high rate. The respective aggregate frequencies of hydrocele and leg lymphedema were 15 percent and 5 percent before the trial began, and 5 percent (P<0.001) and 4 percent (P=0.04) after five years. Hydrocele and leg lymphedema were eliminated in 87 percent and 69 percent, respectively, of those who had these conditions at the outset. The rate of transmission by mosquitoes decreased substantially, and new microfilariae-positive infections in children were almost completely prevented over the five-year study period.
Annual mass treatment with drugs such as diethylcarbamazine can virtually eliminate the reservoir of microfilariae and greatly reduce the frequency of clinical lymphatic abnormalities due to bancroftian filariasis. Eradication may be possible in areas with moderate rates of transmission, but longer periods of treatment or additional control measures may be necessary in areas with high rates of transmission.
全球根除班氏丝虫病倡议目前依赖于每年使用四至六剂抗丝虫药物进行群体治疗。目标是将血液中微丝蚴的储存库减少到不足以维持蚊媒传播的水平。
在巴布亚新几内亚近2500名居民中,我们前瞻性评估了单剂量乙胺嗪加伊维菌素或单独使用乙胺嗪进行四年治疗对微丝蚴阳性感染发生率、淋巴疾病严重程度以及班氏吴策线虫蚊媒传播率的影响。根据居住村庄进行治疗方案的随机分配,村庄被分类为传播率中等或高的地区。
至少五岁的人群中77%至86%的成员接受了两种药物方案中的任何一种的四年治疗;治疗耐受性良好。微丝蚴阳性感染的比例下降了86%至98%,传播率中等地区的下降幅度大于高传播率地区。试验开始前鞘膜积液和腿部淋巴水肿的总发生率分别为15%和5%,五年后分别为5%(P<0.001)和4%(P=0.04)。最初患有这些疾病的人中,分别有87%和69%的鞘膜积液和腿部淋巴水肿得到消除。蚊媒传播率大幅下降,在五年的研究期间几乎完全预防了儿童新的微丝蚴阳性感染。
每年使用乙胺嗪等药物进行群体治疗几乎可以消除微丝蚴储存库,并大大降低班氏丝虫病所致临床淋巴异常的发生率。在传播率中等的地区可能实现根除,但在传播率高的地区可能需要更长的治疗时间或额外的控制措施。